Researchers are developing liquid nanoparticles to bypass the barriers posed by thick mucus and frequent infections in cystic fibrosis lungs and prevent antimicrobial resistance.
Fast-growing bacteria can develop antibiotic resistance through the higher expression of active ribosomes, according to a study published today in eLife.
A new study has found that telavancin, a current treatment for hospital-acquired pneumonia, could be a potential treatment against MRSA in patients with cystic fibrosis.
